Table II.

Acute and chronic GVHD.

Variable	All patients
	Cumulative incidence (95% CI)
	Conventional GVHD prophylaxis (n = 65)`	PTCy (n = 40)	HR; 95% CI	P-value
Acute GVHD, day +30
Grade II–IV	15% (9–27%)	0%	NE	0.01
Grade III–IV	8% (3–18%)	0%	NE	0.08
Acute GVHD, day +100
Grade II–IV	36% (26–50)	37% (25–56)	0.9 (0.5–1.8)	0.8
Grade III–IV	12% (6–23)	17% (9–34)	1.4 (0.5–3.9)	0.5
Chronic GVHD
6 months	15% (8–31)	20% (9–44)	1 (0.6–1.7)	0.9
1 year	31% (19–50)	30% (16–57)	0.95 (0.6–1.5)	0.8
2 years	42% (27–68)	30% (16–57)	0.9 (0.5–1.4)	0.6

Variable	Bone marrow grafts only		7/8-HLA matched patients (n = 84)
	PTCy (n = 34) vs. Conventional GVHD prophylaxis (n = 45)		PTCy (n = 38) vs. Conventional GVHD prophylaxis (n = 46)*
	HR; 95% CI	P-value	HR; 95% CI	P-value
Acute GVHD, day +30
Grade II–IV	NE	0.03	NE	0.005
Grade III–IV	NE	0.2	–	–
Acute GVHD, day +100
Grade II–IV	0.9 (0.4–1.8)	0.8	1 (0.5–2.1)	0.9
Grade III–IV	1.9 (0.5–6.7)	0.3	1.1 (0.3–3.3)	0.9
Chronic GVHD
6 months	1.2 (0.3–4.6)	0.8	0.8 (0.2–2.9)	0.7
1 year	0.8 (0.3–2.6)	0.8	0.8 (0.3–2.2)	0.6
2 years	0.6 (0.2–1.9)	0.4	0.7 (0.2–1.9)	0.5

CI, Confidence Interval; HR, Hazard Ratio; GVHD, graft-versus-host disease; PTCy, Post-transplant cyclophosphamide; HLA, Human Leucocyte Antigen; NE, not evaluable.

^*Acute GVHD data missing for one engrafted patient in the conventional GVHD prophylaxis group.